# Recombinant Human Growth Hormone (RH-GH) For Accelerating Immune Reconstitution Post Unrelated Cord Blood Transplant

> **NCT00737113** · PHASE1 · TERMINATED · sponsor: **Mitchell Horwitz, MD** · enrollment: 14 (actual)

## Conditions studied

- Allogeneic Stem Cell Transplantation

## Interventions

- **DRUG:** Genotropin (Recombinant Human Growth Hormone)

## Key facts

- **NCT ID:** NCT00737113
- **Lead sponsor:** Mitchell Horwitz, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-09
- **Primary completion:** 2012-05
- **Final completion:** 2013-12
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Study was terminated early due to low accrual.
- **Last updated:** 2014-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00737113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00737113, "Recombinant Human Growth Hormone (RH-GH) For Accelerating Immune Reconstitution Post Unrelated Cord Blood Transplant". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00737113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*